3rd Quarter - Report

BIOCOM for BIOCOM

Period 3rd Quarter 2012 Filed Oct 26, 2012 Signed by Mary Fromson, Executive Assistant

Official filing
Firm
BIOCOM
Client
BIOCOM
Income
—
Expenses
$40,217
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Energy/Nuclear ENG

- Discussed biomass and renewable energy sector in California

LobbyistCovered position, as disclosed
JOE PANETTA —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

- Voiced support for Medical Device Excise Tax Repeal Efforts, HR 463

LobbyistCovered position, as disclosed
JOE PANETTA —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: H.R. 463 (112th)

Health Issues HCR

Discussed issues regarding possible future collaboration for communication with the life science industry, concerns raised regarding regulatory enforcement practices, implementation of biologics user fees.

LobbyistCovered position, as disclosed
JOE PANETTA —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.